Multicenter lupus register from Argentina,the RELESSAR database: Influence of ethnicity on disease phenotype

Abstract

Objective

The objective is to describe the main characteristics of patients with systemic lupus erythematosus (SLE) in Argentina and to examine the influence of ethnicity on the expression of the disease.

Patients and methods

RELESSAR is a multicentre register carried out by 106 researchers from 67 rheumatologic Argentine centres. It is a cross-sectional study of SLE (1982/1997 ACR) patients. RELESSAR electronic database includes demographic, cumulative SLE manifestations, SELENA-SLEDAI, SLICC-SDI, Katz’s severity and Charlson’s comorbidity indexes and treatment patterns.

Results

We included 1,610 patients, 91.7% were female with a median age at diagnosis of 28.1 ± 12.8; 96.2% met ≥4 ACR 1982/97 criteria. Frequent manifestations were arthritis (83.5%), malar rash (79.5%), photosensitivity (75.3%), haematological (63.8%) and renal disease (47.4%), antinuclear antibodies (96%), anti-dsDNA (66.5%) and anti-Smith antibodies (29%). The mean Selena-SLEDAI score at last visit was 3.18 (SD 4.3) and mean SDI was 1 (SD 1.3). The accumulated treatments most frequently used were antimalarials (90.4%), corticosteroids (90%), azathioprine (31.8%), intravenous cyclophosphamide (30.2%), mycophenolate mofetil or mycophenolic acid (24.5%), methotrexate (19.3%), belimumab 5.3% and rituximab 5.1%. Refractory lupus was diagnosed in 9.3% of the cases. The main causes of death were lupus activity (25.0%), activity and concomitant infections (25.0%), infections (18.2%), vascular disease (13.6%) and cancer (4.5%). Mortality was associated with higher SLEDAI, Katz, damage indexes and comorbidities. Of the 1610 patients included, 44.6% were Caucasian, 44.5% Mestizo, 8.1% Amerindian and 1.2% Afro-Latin American. Mestizo patients had higher male representation, low socioeconomic status, more inadequate medical coverage, fewer formal years of education and shorter disease duration. Polyadenopathies and Raynaud’s phenomenon were more frequent in Caucasians. In the logistic regression analysis higher damage index (OR 1.28, CI 95% 1.02–1.61, p = 0.03) remained associated to mestizo ethnicity.

Conclusions

This study represents the largest number of adult patients with SLE studied in Argentina. Caucasian patients were differentiated by having Raynaud’s phenomenon and polyadenopathy more frequently, while patients of Mestizo origin had higher damage indexes.

Keywords

Systemic lupus erythematosus ethnicity systemic lupus erythematosus in Argentina

Get full access to this article

View all access options for this article.

References

Scolnik

Marin

Valeiras

, et al. Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organization-based study. Lupus Sci Med 2014; 1(1): e000021.

Gonzalez Lucero

Barbaglia

Bellomio

, et al. Prevalence and Incidence of Systemic Lupus Erythematosus in Tucuman -Argentina. Lupus.2020; 29(13): 1815–1820.

Rúa-Figueroa

López-Longo

Calvo-Alen

, et al. Registro Nacional de pacientes con Lupus Eritematoso Sistémico de la Sociedad Española de Reumatología: objetivos y epidemiología. Reumatol Clin 2014; 10(1): 17–24.

Ugarte-Gil

Pimentel-Quiroz

Vilá

, et al. Factors associated with disease expression patterns in systemic lupus erythematosus patients: results from LUMINA (LXXVII), a multiethnic US cohort. Lupus. 2017; 26(6): 650–655.

Pimentel-Quiroz

Ugarte-Gil

Harvey

, et al. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus 2019; 28(9): 1101–1110.

Tan

Cohen

Fries

, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

Graffar

. Une methode de classification sociale d’echantillons de population. Courrier VI 1956: 445–459.

Hawker

Gabriel

Bombardier

, et al. A reliability study of SLEDAI: A disease activity index for systemic lupus erythematosus. J Rheumatol 1993; 20: 657–660.

10.

Gladman

Ginzler

Goldsmith

, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

11.

Katz

Senecal

Rivest

, et al. A simple severity of disease index for systemic lupus erythematosus. Lupus 1993; 2: 119–123.

12.

Charlson

Szatrowski

Peterson

, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251.

13.

Pons-Estel

Catoggio

Cardiel

, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus ethnic and disease heterogeneity among ‘‘hispanics”’. Medicine 2004; 83: 1–17.

14.

Ramírez Gómez

Uribe Uribe

Osio Uribe

, et al. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 2008; 17(6): 596–604.

15.

Ugarte-Gil

Wojdyla

Pons-Estel

, et al. Predictors of remission and low disease activity state in systemic lupus erythematosus: data from a multi-ethnic, multinational Latin-American Lupus Cohort. J Rheumatol 2019; 46(10): 1299–1308.

16.

Oglesby

Korves

Laliberté , et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy 2014; 12(2): 179–190.

17.

Cervera

Abarca-Costalago

Abramovicz

, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". Autoimmun Rev 2006; 5(3): 180–186.

18.

Pons-Estel

Bonfa

Soriano

, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis 2018; 77(11): 1549–1557.

19.

Luo

Mao

Zhang

, et al. Association between systemic lupus erythematosus and thyroid dysfunction: a meta-analysis Lupus 2018; 27: 2120–2128.

20.

Jang

Dooley

Joy

. Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis. Ann Pharmacother 2013; 47(7–8): e35.

21.

van Vollenhoven

Voskuyl

Bertsias

et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76(3): 554–561.

22.

Pego-Reigosa

Lois-Iglesias

Rúa-Figueroa

, et al. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. Rheumatology (Oxford) 2016; 55(7): 1243–1250.

23.

Miranda-Hernández

Cruz-Reyes

Angeles

, et al. Prognostic factors for treatment response in patients with lupus nephritis. Reumatol Clin 2014; 10(3): 164–169.

24.

Seldin

Scherbarth

, et al. Amerindian ancestry in Argentina is associated with increased risk for systemic lupus erythematosus. Genes Immun 2008; 9(4): 389–393.

25.

Hernández Cruz

Alonso

Calvo Alén

, et al. RELESSER (Spanish Society of Rheumatology Systemic Lupus Erythematosus register) group. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus 2020; 29(1): 27–36.

26.

Pons-Estel

Alarcón

Burgos

, et al. Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus 2013; 22(9): 899–907.

27.

Pons-Estel

Ugarte-Gil

Harvey

, et al. Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. RMD Open 2020; 6(1): e001097.

28.

Aringer

Costenbader

Daikh

, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Ann Rheum Dis 2019; 78(9): 1151–1159.

29.

Alarcón

Ugarte-Gil

Pons-Estel

, et al. Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort. Lupus 2019; 28(3): 423–426.

30.

Torrente-Segarra

Salman Monte

Rúa-Figueroa

, et al. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Semin Arthritis Rheum 2019; 48(6): 1025–1029.

31.

Ugarte-Gil

González

Alarcón

. Lupus: the new epidemic. Lupus 2019; 28(9): 1031–1050.